Trial Profile
A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 2-Parallel Group, Phase III Study to Compare Efficacy and Safety of Masitinib 9 mg/kg/Day in Combination With Gemcitabine Compared to Placebo in Combination With Gemcitabine in Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 Dec 2018
Price :
$35
*
At a glance
- Drugs Masitinib (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Registrational; Therapeutic Use
- Sponsors AB Science
- 27 Nov 2018 Status changed from active, no longer recruiting to completed.
- 09 Apr 2015 According to AB Science media release, results published in the journal Annals of Oncology.
- 09 Apr 2015 Results (Subgroup analysis) published in the AB Science Media Release.